RxDoctor Payments Data

Rajdeep Ranade, MD

Psychiatry · Sacramento, CANPI 1164614400

Payments from drug & device makers

$2,048in general payments, 2019–2025

Across 159 payments — averaging $12.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • Bausch Health US, LLC$279
  • Lundbeck LLC$266
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$226
  • Teva Pharmaceuticals USA, Inc.$211
  • Otsuka America Pharmaceutical, Inc.$100
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$2,00198%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,048 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$65,713
Medicare patients
53
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate39$112,986
IngrezzaValbenazine Tosylate15$109,234
VraylarCariprazine Hcl28$39,259
RexultiBrexpiprazole20$28,332
Clozapine229$23,226
Lurasidone Hcl28$11,050
Chlorpromazine Hcl30$8,558
MyrbetriqMirabegron15$6,192
BelsomraSuvorexant11$4,705
Divalproex Sodium ErDivalproex Sodium37$4,475
Lisdexamfetamine Dimesylate14$3,429
Lactulose15$2,704
Olanzapine78$2,628
Quetiapine Fumarate162$2,133
Icosapent Ethyl11$2,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$880$39,25928 claims
Otsuka America Pharmaceutical, Inc.Rexulti$100$28,33220 claims
MerckBelsomra$18$4,70511 claims
Almatica Pharma LLCSertraline Hcl$14$51846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →